HighVista Strategies’s Rhythm Pharmaceuticals RYTM Stock Holding History

HighVista Strategies’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Sell	16,796 -26,071	-61%	-$2.54M	0.4%	79
2025 Q4	$4.59M	Buy	42,867 +5,385	+14%	+$571K	1.18%	25
2025 Q3	$3.79M	Buy	37,482 +9,414	+34%	+$874K	0.93%	29
2025 Q2	$1.77M	Sell	28,068 -6,971	-20%	-$427K	0.65%	53
2025 Q1	$1.86M	Sell	35,039 -2,387	-6%	-$132K	0.72%	47
2024 Q4	$2.1M	Hold	37,426	–	–	0.78%	42
2024 Q3	$1.96M	Buy	37,426 +23,064	+161%	+$1.11M	0.68%	46
2024 Q2	$590K	Hold	14,362	–	–	0.22%	114
2024 Q1	$622K	Hold	14,362	–	–	0.22%	110
2023 Q4	$660K	Buy	+14,362	New	+$453K	0.24%	106
2023 Q2	–	Sell	-35,478	Closed	-$633K	–	151
2023 Q1	$633K	Hold	35,478	–	–	0.52%	66
2022 Q4	$1.03M	Buy	+35,478	New	+$912K	0.61%	41
2021 Q2	–	Sell	-24,809	Closed	-$528K	–	136
2021 Q1	$528K	Buy	+24,809	New	+$720K	0.39%	68
2020 Q3	–	Sell	-18,609	Closed	-$415K	–	127
2020 Q2	$415K	Buy	+18,609	New	+$363K	0.34%	57

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HighVista Strategies's RYTM Position: Q1 2026 in Review

HighVista Strategies reduced its Rhythm Pharmaceuticals (RYTM) stake by 61% in Q1 2026, selling an estimated $2.54M and leaving 16,796 shares worth $1.46M. The position accounts for 0.4% of the portfolio, ranked #79.

HighVista Strategies first reported a position in RYTM in Q2 2020 and has held it in 14 quarters since. The position peaked at $4.59M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

HighVista Strategies held 16,796 shares of Rhythm Pharmaceuticals worth $1.46M as of Q1 2026.
HighVista Strategies sold 26,071 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $2.54M.
Rhythm Pharmaceuticals made up 0.4% of HighVista Strategies's portfolio in Q1 2026, its #79 holding.
HighVista Strategies first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
HighVista Strategies's Rhythm Pharmaceuticals position peaked at $4.59M in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.